Primary Biliary Cholangitis Treatment: What Works in 2026
As of 2026, Primary Biliary Cholangitis treatment has shifted dramatically with the withdrawal of Ocaliva and the rise of seladelpar and elafibranor. Learn how UDCA, new PPAR agonists, and monitoring strategies are changing outcomes for patients.
Continue Reading
